Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH). The data revealed that ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Cardinal Health (CAH), which belongs to ...

Discover key insights from Neurocrine Biosciences' Q2 2025 earnings, featuring record INGREZZA growth, CRENESSITY's rapid adoption, and strategic ...

Stay up to date on how Cardinal Health Inc (CAH:XNYS) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.

Cardinal Health, Inc. (CAH) dividend yield: annual payout, 4 year average yield, yield chart and 10 year yield history.

See the latest Cardinal Health Inc stock price (CAH:XNYS), related news, valuation, dividends and more to help you make your investing decisions.

Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cardinal Health, Inc. CAH reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of $2.35, which beat the Zacks Consensus Estimate of $2.15 by 9.3%. The bottom line also improved 12. ...